年赚35.7亿元的京东健康，却还是摆脱不了"互联网大药房"的标签。日前，京东健康发布了2025年上半年业绩报告，GPLP犀牛财经注意到，在这份财报 中，收入、盈利以及毛利等多重核心指标上，都体现出了京东健康的增长韧性。 从业务构成来看，2025上半年，京东健康医药和健康产品销售贡献收入293亿元，同比增长22.7%；线上平台、数字化营销及其他服务贡献收入60亿元，同 比增长34.4%。 京东健康营销上的投入同样水涨船高。2025年上半年，京东健康销售及市场推广开支为18亿元，同比增长28.8%，主要因推广及广告开支增加及提供的技术 和流量支持服务开支增加。 2025年上半年，京东健康收入为352.90亿元，同比增长24.5%；非国际财务报告准则下的盈利为35.7亿元，同比增长35.0%；毛利为88.92亿元，同比增长 32.7%。 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 同比變動 | | | 人民幣千元 | 人民幣千元 | (%) | | | (未經審計) | (未經審計) | | | 收入 | 35,290,04 ...

Core Insights - JD Health's stock rose over 10% following the release of its interim results, with a current price of HKD 60.7 and a trading volume of HKD 2.19 billion [1] Financial Performance - For the six months ending June 30, 2025, JD Health reported revenue of RMB 35.29 billion, a year-on-year increase of 24.5% [1] - Non-IFRS profit for the same period was RMB 3.57 billion, up 35% year-on-year [1] - Net profit attributable to shareholders was RMB 2.596 billion, reflecting a 27.45% increase year-on-year [1] - Basic earnings per share were RMB 0.82 [1] Revenue Breakdown - Revenue for the three months ending June 30, 2025, increased by 23.7% to RMB 18.6 billion compared to the previous year [1] - Revenue from the sale of pharmaceutical and health products rose from RMB 23.9 billion to RMB 29.3 billion, marking a 22.7% increase [1] - Growth in product revenue was driven by an increase in active user numbers, additional purchases by users, higher online penetration rates for pharmaceutical and health products, and a wider range of product categories [1] Service Revenue Growth - Service revenue from online platforms and digital marketing increased by 34.4%, from RMB 4.4 billion to RMB 6 billion [2] - The growth in service revenue was primarily due to an increase in digital marketing service fees, attributed to a rise in the number of advertisers on the platform and consistent growth in transactions [2]